

## NEWS RELEASE

**Eurocor Enters into Licensing Agreement with Biosensors  
for Drug-eluting Balloon Range**

Bonn, Germany | Singapore | 31 May 2013

*Eurocor has undertaken to no longer use one sentence which was contained in the initial version of the press release. The sentence which was correspondingly amended is marked in bold in the new version of the press release below.*

Eurocor GmbH, a group company of Opto Circuits (India) Ltd. (Bloomberg: OPTC IN; Reuters: OPTO. NS; NSE OPTOCIRCU; BSE: 532391), has entered into a licensing agreement with Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices. **The agreement pertains to the former's Drug Eluting Balloon (DEB) technology and the related German utility model (DE 20 2010 017 248) as well as several pending patent applications in relation to the treatment of both coronary and peripheral artery disease (European Patent application EP 2421572 and other national patent applications).** As a first step in this process, an Original Equipment Manufacturer (OEM) arrangement is being implemented, whereby Biosensors will market and sell, under its own brand, DEBs manufactured by Eurocor.

Both agreements will involve three Biosensors-branded DEBs: BioStream™; BioPath™ 014; and BioPath™ 035. All three devices are drug-eluting balloon dilatation catheters designed for percutaneous transluminal angioplasty (PTA): BioStream has been developed for use in coronary arteries; the two BioPath DEBs have been optimized for the treatment of patients with peripheral arterial disease. BioPath 035 is intended for peripheral intervention above the knee and BioPath 014 for infrapopliteal intervention below the knee.

All three DEBs feature Eurocor's coating technology delivering paclitaxel, an antirestenotic drug proven in DEB applications. The coating technology has been proven in several clinical studies performed by Eurocor, including the global Valentine I and II studies. The proprietary coating employed in these DEB products is capable of delivering the antirestenotic drug consistently during very brief inflation times, while also minimizing washout of the drug during delivery and placement of the DEB.

"We are delighted to have acquired a new range of DEBs as a result of this licensing agreement with Eurocor", commented Jeffrey B. Jump, President of Biosensors' Cardiovascular Division. "These innovative devices will complement our existing portfolio of cardiac stents, and facilitate our entry into the peripheral vascular disease market."

Following CE Mark approval currently anticipated within the next six weeks, BioStream, BioPath 014 and BioPath 035 will be launched in major European markets and selected regions in the Middle East, Africa and Asia.

"This agreement is further validation for Eurocor's DEB products. There is considerable scope for global expansion within this rapidly-growing sector of the interventional devices market," added Dr. Antonino Laudani, COO of Eurocor GmbH. "We are looking forward to working

closely with Biosensors to further the process of establishing Eurocor as one of the leading global providers of innovative DEB products”.

"This arrangement with Eurocor is a positive development in the broadening of our cardiovascular business”, concluded Dr Jack Wang, CEO of Biosensors. “It also marks the first step in our expansion into the peripheral business.”

**For further information, please contact:**

<u>Eurocor GmbH Press Office</u> Claudia Tischendorf +49 (0) 228 201 50 26 <a href="mailto:pressoffice@eurocor.de">pressoffice@eurocor.de</a>	<u>Opto Circuits Investor Relations</u> +91 80 2852 8088 <a href="mailto:ir@optoindia.com">ir@optoindia.com</a>
<u>Biosensors Corporate Communications</u> Richard Kenyon Biosensors International Group +44 7831 569940 <a href="mailto:r.kenyon@biosensors.com">r.kenyon@biosensors.com</a>	<u>Biosensors Investor Relations</u> Wong Teck Yenn Biosensors International Group +65 6213 5708 <a href="mailto:ty.wong@biosensors.com">ty.wong@biosensors.com</a>

**About: Eurocor GmbH**

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Europe. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead® – with innovative products such as DIOR® and FREEWAY™.

Eurocor GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of the Opto Circuits Group. For more information, please visit [www.eurocor.de](http://www.eurocor.de).

**About: Opto Circuits (India) Limited**

Opto Circuits (India) Ltd. (OCI) is a vertically integrated multinational medical technology Group that specializes in primary, acute and critical care products for the global markets. Group companies such as Cardiac Science, Criticare, Eurocor, Mediaid, AMDL and Unetixs Vascular are leaders in vital signs monitors, emergency cardiac care equipment, vascular treatments and sensing technologies. Our USFDA listed and CE marked products are marketed in more than 150 countries and sold through direct and indirect sales channels across many emerging and developed economies. We’ve been ranked in Forbes’ Asia’s 200 Best under a Billion lists in 2008, 2009 and 2011. For more information, please visit [www.optoindia.com](http://www.optoindia.com).

**About: Biosensors International Group Ltd.**

Biosensors International develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients’ lives through pioneering medical technology that pushes forward the boundaries of innovation.

With the increasing use of the BioMatrix™ family of drug-eluting stents and the recent launch of our Axxess™ self-expanding bifurcation drug-eluting stent, we are rapidly emerging as a leader



in the global coronary stent market. The development of the BioFreedom™ drug-coated stent will further reinforce our market position.

All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water after six to nine months as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer-free stent abluminally coated with BA9, received CE Mark Approval in January 2013.

For more information, please visit [www.biosensors.com](http://www.biosensors.com)